Image source: Getty Images.
Continue Reading Below
After reporting third-quarter results below industry watchers' forecast and lowering full-year guidance,Impax Laboratories (NASDAQ: IPXL)shares are dropping 23.44% at 2:00 p.m. EST Wednesday.
The generic drug company's sales increased 3.1% year over year to $227.9 million, and EPS came in at $0.37. Analysts were looking for sales and EPS of $234.75 million and $0.39, respectively.
In the quarter, a 30% increase in specialty pharmaceuticals sales due to higher sales of Rytaryand Zomig nasal spray were offset by a 3% decline in the company's generic drug segment. Generic drug sales were negatively impacted by market share losses on the company'sdiclofenac sodium gel 3%, mixed amphetamine salts, and metaxalone.
Continue Reading Below
The performance led management to lower its full-year sales outlook to between$840 million and $855 million from previously announced expectations of between $900 million and $940 million. Management also cut its adjusted EPS guidance to $1.10 to $1.20 from $1.57 to $1.70.
"Our third quarter 2016 results reflect the volatility we have experienced as a result of additional competition on a few of our largest generic products," saidFred Wilkinson, President and Chief Executive Officer of Impax. "Successful marketing and operational strategies are helping us to capitalize on several generic opportunities, including epinephrine auto-injector and oxymorphone, and we defended our share position across the majority of our generic portfolio. That said, the ongoing impact of an increasingly challenging market environment continues to weigh on our results and consequently we are revising our outlook for fiscal 2016 to reflect the impact of lower pricing across an increased number of products in our generic portfolio."
Impax Laboratories recently acquired 15 generic drugs from Teva Pharmaceuticaland that did offset some of the headwind from lost diclofenac sales. Sales and profit uncertainty, however, remains a big overhang on this company's stock. Until it can prove to investors that it's overcoming obstacles, I think it's best to focus on other investment ideas that have a clearer path to upside.
10 stocks we like better than Impax Laboratories
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Impax Laboratories wasn't one of them! That's right -- they think these 10 stocks are even better buys.
Click here to learn about these picks!
*Stock Advisor returns as of November 7, 2016
Todd Campbell has no position in any stocks mentioned.Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned.Like this article? Follow him onTwitter where he goes by the handle@ebcapitalto see more articles like this.
The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.